mPhase Technologies Inc (XDSL)

[ALDACON]

Ran across this info on MPhase little dated but interesting,
CLIFTON, NJ / ACCESSWIRE / January 26, 2016 / mPhase Technologies, Inc. (XDSL) (http://www.mPhaseTech.com) said today that its new, patented Drug Delivery System could prove especially useful and efficacious for patients taking insulin for diabetes, according to Company research.

Ronald A. Durando, the Company's Chairman, President and CEO, said mPhase Technologies' new invention automatically dispenses a pre-set dosage of a drug such as insulin, which is vital in maintaining proper blood sugar levels in individuals with diabetes. "Every method to deliver insulin currently used has proven to have some problems," Mr. Durando explains.

"Some patients use insulin pens which are pre-filled with insulin." Mr. Durando said. "Syringes may still be the most common way to deliver insulin. Problems include the number of steps needed to be taken before the injection: and drawing the correct dose of insulin into the syringe. Because both of these methods are done manually, human errors occur and sometimes the correct dosage is not administered."

"The insulin pump, delivers a steady stream of insulin 24 hours a day along with the user calculating meal bolus amounts. Disadvantages of the pump can be that one must frequently change the needle to avoid infection, dosing errors, and some people are not comfortable having the unit attached to them 24 hours a day," the mPhase Technologies CEO said. Additionally, blood sugar levels need to be tracked frequently for drops in blood sugar.

"A jet injector is used by people who hate needles, but it can be painful and does not always deliver an accurate dose. Inhaled insulin can prove risky for those who smoke or have any lung problems," Mr. Durando said.

In addition, new methods of delivering insulin have been introduced that deliver dosing through the skin, with very fine needles that penetrate the skin. In addition, new Insulin Patches are also being explored that use various methods to drive insulin through the skin. They work in a similar way to nicotine patches used by smokers to help them quit.

"Now that we have received a Notice of Allowance of a Patent for our new Drug Delivery System, we look forward to discussing our product with major drug companies," Mr. Durando concluded.